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Hereditary sensory neuropathy type I (HSN I) is a group of dominantly inherited degenerative disorders of peripheral
nerve in which sensory features are more prominent than motor involvement. We have described a new form of
HSN I that is associated with cough and gastroesophageal reﬂux. To map the chromosomal location of the gene
causing the disorder, a 10-cM genome screen was undertaken in a large Australian family. Two-point analysis
showed linkage to chromosome 3p22-p24 ( at recombination fraction (v) 0.0 for marker D3S2338).Z p 3.51max
A second family with a similar phenotype shares a different disease haplotype but segregates at the same locus.
Extended haplotype analysis has reﬁned the region to a 3.42-cM interval, ﬂanked by markers D3S2336 and
D3S1266.
The hereditary motor and sensory neuropathies are a ge-
netically heterogeneous group of disorders, caused by a
number of different gene mutations. Neuropathies with
predominantly sensory features are classiﬁed as hereditary
sensory neuropathies (HSNs). The autosomal dominant
form of HSN is classiﬁed as hereditary sensory neurop-
athy type I (HSN I) (Thomas 1993). HSN has an adult
onset, generally between the 2nd and 4th decade, with
sensory loss ﬁrst affecting the feet and legs, leading to
painless injuries. Later, foot ulcers, lancinating pains, and
motor involvement can occur (Hicks 1922; Thomas1993;
Nicholson et al. 1996).
Mutations in subunit 1 (SPTLC1) of the enzyme serine
palmitoyltransferase (SPT), the rate-limiting enzyme of
the sphingolipid pathway, have been identiﬁed as the
cause of HSN1 on chromosome 9q22.1-q22.3 (MIM
#162400) (Dawkins et al. 2001). Bejaoui et al. (2001)
have shown that SPTLC1 mutations result in reduced
SPT activity and sphingolipid synthesis but do not alter
the levels of SPTLC1 or SPT subunit 2; this result in-
dicates that the mutations have a predominantly nega-
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tive effect on the SPT enzyme. Another neuropathy, clas-
siﬁed as hereditary motor and sensory neuropathy type
IIB (HMSN IIB), involves severe sensory impairment and
foot ulcers and could therefore be regarded as a form
of HSN (Vance et al. 1996). HMSN IIB has beenmapped
to chromosome 3q13-q22 (Kwon et al. 1995). Two mis-
sense mutations in the RAB7 gene have been identiﬁed
for the HMSN IIB phenotype (Verhoeven et al. 2003).
Approximately 25% of the general population ex-
periences gastroesophageal reﬂux (GER) (Nebel et al.
1976). In some cases, it is an inherited trait (Crabb et
al. 1985), but, for the most part, it is attributed to the
effects of diet, obesity, or hiatus hernia. Two forms of
dominantly inherited GER have been identiﬁed. A form
of severe GER in children was mapped to chromo-
some 13q14 (Hu et al. 2000), and an inherited form
of GER with autosomal dominant spastic paraparesis
was mapped to chromosome 10q (Seri et al. 1999).
As many as 25% of patients with GER symptoms have
associated respiratory manifestations, including cough
(Poe et al. 1989; Irwin et al. 1990, 1993). In many of
these individuals, cough may be the only manifestation
of GER (Irwin et al. 1989).
HSN I with cough and GER was recently identiﬁed
by two authors of the present report (J.D.P. and P.J.S.),
and detailed clinical and neurophysiological studies of
this family have been described elsewhere (Spring et al.
2002). The ﬁrst symptoms of HSN I with cough and
GER can be an unexplained chronic cough, which can
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progress to cough syncope. Monitoring of esophageal
pH for 24 h shows that cough is temporally associated
with GER and impaired laryngeal sensation. The dis-
order usually presents in adult life, with either cough or
GER symptoms. The cough may occur between the 2nd
and the 4th decade. Sensory loss commences in the feet
and legs, between the 3rd and 5th decade. The Achilles
tendon reﬂexes are decreased in some individuals, and
nerve-conduction–velocity studies show an axonal neu-
ropathy with absent or reduced sensory nerve action
potentials. Nerve biopsy shows loss of unmyelinated and
myelinated axons.
We have identiﬁed two families with HSN I with
cough and GER. One, a three-generation Australian
family (HSN32), was large enough for linkage studies.
Male-to-male transmissions indicated autosomal domi-
nant inheritance. A total of 20 at-risk individuals in this
family and 7 spouses were recruited for clinical, elec-
trophysiological, and genetic studies, after obtaining in-
formed consent according to guidelines of the Concord
Hospital medical ethics review committee. A second, un-
related family (HSN35) with nine at-risk family mem-
bers and two spouses was large enough for haplotype
studies.
Individuals were classiﬁed as affected, for the purpose
of the linkage study, if they had a neuropathy and either
a chronic cough or GER or both. The cough must have
no other cause and be present at least 1 year. Initially,
the cough may appear if the patient is repeatedly clearing
the throat. The features of the neuropathy are sensory
loss, painless injuries, or lancinating pains, with or with-
out abnormal results of nerve-conduction studies that
are consistent with an axonal neuropathy. GER is in-
dicated by the occurrence of heartburn, regurgitation,
or acid brash at least once a week. When clinically in-
dicated, some individuals underwent a dual-probe 24-h
ambulatory esophageal pH monitoring with a subject-
triggered cough sensor (as described by Ing et al. [1994]).
Episodes of reﬂux are detected by a reduction in pH to
!4 in the distal or proximal esophagus, and these may
be correlated with episodes of cough. Obligate carriers,
deﬁned as those family members who had affected off-
spring, were assigned to the affected group. Individuals
with a chronic cough or GER without neuropathy were
classiﬁed as having an unknown clinical phenotype. In-
dividuals with no relevant symptoms and with normal
results on clinical examination were assigned to the un-
affected group. Eight members of family HSN32 were
classiﬁed as affected. Of these, one individual did not
have all three phenotypes. Six individuals were classiﬁed
as unaffected, and six were classiﬁed as having unknown
clinical status. Two of the individuals with unknown
clinical status were obligate carriers. In family HSN35,
two individuals were classiﬁed as affected. Both had all
three phenotypes. Five individuals were classiﬁed as un-
affected, and two individuals had an unknown clinical
status. One of the individuals with unknown clinical
status was an obligate carrier.
Genomic DNAwas extracted fromwhole blood, using
standard techniques. Known loci for HSN I (HSN1
[Nicholson et al. 1996]), HMSN I (HMSN IA [Valentijn
et al.1992] and HMSN IB [Bird et al. 1983]), HMSN II
(HMSN IIA [Ben Othmane et al. 1993], HMSN IIB
[Kwon et al. 1995], HMSN IID [Ionasescu et al. 1996],
HMSN IIE [Mersiyanova et al. 2000], and HMSN IIF
[Ismailov et al. 2001]) were excluded by either linkage
analysis or mutation screening. The pediatric GER locus
and the hereditary spastic paraplegia locus were also
excluded (data not shown) (Seri et al. 1999; Hu et al.
2000). A genomewide screen using 383 microsatellite
markers at 10-cM intervals was undertaken at the Aus-
tralian Genome Research Facility. Autosomal dominant
inheritance was assumed, with 95% penetrance by the
age of 35 years. A disease allele frequency of 0.001 and
a phenocopy rate of 0.001 were assumed (Seri et al.
1999). Male and female recombination rates were con-
sidered equal. Marker allele frequencies were obtained
from the Genome Database. DNA samples were ampli-
ﬁed by PCR, as described by Nicholson et al. (1996).
The computer program MLINK was used to perform
two-point linkage analysis (Lathrop et al. 1984). Hap-
lotypes were assigned on the basis of the minimization
of intermarker recombination.
The genome screen showed linkage to chromosome
3p22-p24. Marker D3S2338 gave a LOD score of 3.51
at recombination fraction (v) 0.0. Elsewhere in the ge-
nome, no other signiﬁcantly positive LOD score peaks
were detected. Linkage studies, in which individuals ex-
pressing two of the three phenotypes were assigned a
different affection status, showed no signiﬁcant change
in the LOD scores and no other signiﬁcantly positive
LOD score peaks elsewhere in the genome. Nine addi-
tional markers within this region were then tested in
both families. The results of the two-point linkage anal-
ysis are shown in table 1. Extended haplotypes were
constructed according to the order of the Marshﬁeld
genetic map (ﬁg. 1). The disease haplotypes segregating
in families HSN32 and HSN35 are shown in ﬁgure 2.
A recombinant individual in family HSN32 (individ-
ual III:9) deﬁnes marker D3S1266 as the proximal ﬂank-
ing marker. The distal ﬂanking marker is deﬁned by a
recombination event in family HSN35 (individual III:5),
occurring between markers D3S2336 and D3S2466.
Both of these individuals have the full disease syndrome.
On the basis of these two informative recombination
events, HSN with cough and GER has been localized to
a 3.42-cM region that is ﬂanked by the markers D3S2336
and D3S1266 and corresponds to a physical distance of
3 Mb. The two families do not share a common disease
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Table 1
Pedigrees HSN32 and HSN35 Combined: Two-Point LOD Scores
between the Locus for HSN with Cough and GER and the
Microsatellite on Chromosome 3p
MARKER
AND
PEDIGREE
LOD SCORE AT v(m p f) p
0 .01 .05 .1 .2 .3 .4
D3S1259:
HSN32 2.21 2.23 2.22 2.09 1.66 1.09 .88
HSN35 2.58 1.72 .91 .50 .14 .01 .02
HSN32/35 .37 .51 1.31 1.59 1.52 1.10 .90
D3S3610:
HSN32 .86 .76 .46 .24 .01 .07 .08
HSN35 1.88 1.14 .55 .31 .12 .04 .01
HSN32/35 2.74 1.90 1.01 .55 .13 .03 .07
D3S2403:
HSN32 2.37 2.33 2.15 1.92 1.42 .87 .74
HSN35 .51 .44 .26 .12 .02 .07 .08
HSN32/35 1.86 1.89 1.89 1.80 1.40 .08 .82
D3S1585:
HSN32 2.65 2.61 2.43 2.20 1.70 1.13 1.02
HSN35 1.34 1.18 .77 .46 .13 .01 .02
HSN32/35 1.31 1.43 1.66 1.74 1.57 1.14 1.04
D3S2338:
HSN32 3.51 3.45 3.21 2.88 2.19 1.42 1.32
HSN35 1.46 1.28 .78 .44 .11 .02 .02
HSN32/35 2.05 2.17 2.43 2.44 2.08 1.44 1.34
D3S1293:
HSN32 1.46 1.50 1.57 1.54 1.30 .91 .81
HSN35 2.03 1.05 .38 .09 .12 .17 .18
HSN32/35 .43 .45 1.19 1.45 1.42 1.08 1.18
D3S2336:
HSN32 3.34 3.28 3.04 2.73 2.08 1.36 1.27
HSN35 1.52 .75 .16 .06 .20 .20 .19
HSN32/35 2.82 2.53 2.88 2.79 2.28 1.56 1.46
D3S2466:
HSN32 3.23 3.18 2.95 2.65 2.00 1.29 1.15
HSN35 .63 .63 .61 .58 .50 .38 .31
HSN32/35 3.86 3.81 3.56 3.23 2.50 1.67 1.46
D3S2337:
HSN32 1.56 1.52 1.36 1.16 .76 .40 .32
HSN35 1.36 1.33 1.23 1.11 .84 .55 .41
HSN32/35 2.92 2.85 2.59 2.27 1.50 .95 .73
D3S2335:
HSN32 3.23 3.18 2.95 2.65 2.00 1.29 1.18
HSN35 .04 .04 .03 .02 .01 .00 .00
HSN32/35 3.19 3.14 2.92 2.63 1.99 1.29 1.18
D3S21266:
HSN32 .53 1.50 1.94 1.93 1.59 1.06 .94
HSN35 .97 .34 .21 .41 .49 .40 .33
HSN32/35 .44 1.16 1.73 1.52 1.10 .66 .61
Figure 1 Genetic map (sex averaged) of chromosome 3 markers
used in the present study. The marker-map positions are based on the
sex-averaged maps from the Center for Medical Genetics, Marshﬁeld
Medical Research Foundation. Loci on the same line were mapped to
the same genetic location. Markers ﬂanking the HSN I with cough
and GER genetic interval are shown in boldface.
haplotype, suggesting that different mutations in a single
gene might occur.
We have demonstrated a signiﬁcant linkage score of
3.51 at in one family with cough and GER andvp 0.0
in a second family with a similar phenotype, in which
all affected individuals share a haplotype in the same
region. It could be argued that there are two separate
syndromes affecting these families (GER with chronic
cough and hereditary sensory neuropathy) and that they
occurred together by chance. Because there are no in-
stances of the neuropathy without GER and cough, the
two disorders could be closely linked on the same chro-
mosome or they could be allelic at the same locus. The
natural history of the disease is consistent with all these
features being part of a single disorder, because neurop-
athy is the last feature of the disease to develop. Given
that cough or GER always precedes sensory loss bymany
years, the natural history of the disease explains the pres-
ence of cough or GER without neuropathy in younger
individuals. The oldest individual with cough and GER
but minimal signs of neuropathy was 52 years old at
the time of investigation.
Sporadic cases of GER are found in approximately
one-third of the general population. In a large study in
the British population, Jones and Lydeard (1989) con-
ﬁrmed this ﬁgure, showing that 38% of the population
reported symptoms of GER. Therefore, cases of GER
alone could be explained as being nonhereditary spo-
radic cases. Cough has been estimated to affect 10% of
subjects with GER (i.e., 3% of the population) (Poe et
al. 1989; Irwin et al. 1990, 1993). However, to eliminate
these probabilities, for the linkage study, we assigned an
unknown phenotype to all subjects with GER and/or
cough without neuropathy.
The 3.42-cM interval containing the locus for HSN I
with cough and GER on chromosome 3p22-24 has been
almost completely sequenced and contains 28 mapped
genes. Two positional candidate genes have been iden-
tiﬁed on the basis of their expression proﬁles in periph-
eral nerve and spinal cord through the Entrez Human
Figure 2 Haplotype analysis of markers from chromosome 3p22-p24 in families HSN32 and HSN35 with autosomal dominant HSN I
with cough and GER. The haplotype segregating with the disease is indicated (blackened bar). The markers are presented in order from telomere
(top) to centromere (bottom). Blackened symbols denote affected individuals; unblackened symbols denote unaffected individuals; individuals
with unknown clinical status are denoted by a question mark. Individuals are numbered consecutively in each generation, from left to right.
Individual III:5 in family HSN35 deﬁnes the telomeric boundary of the disease at D3S2336, whereas individual III:9 in family HSN32 deﬁnes
the centromeric boundary at D3S1266.
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Genome Map viewer. These genes include the topo-
isomerase II b (TOP2B) and the solute-carrier family 4
(SLC4A7). The TOP2B gene encodes a DNA topoisom-
erase, an enzyme that controls and alters the topologic
states of DNA (Lang et al. 1998, Jenkins et al. 1992).
Takashima et al. (2002) described the gene tyrosyl-DNA
phosphodiesterase 1 (TDP1) as causing an autosomal
recessive spinocerebellar ataxia with axonal neuropathy.
TDP1 repairs covalently bound I–DNA complexes and
has a function in the DNA repair pathway in humans.
TDP1 dysfunction does not predispose to neoplasia, but
it can cause progressive neuronal disease and death
(Yang et al. 1996; Pouliot et al. 1999). Reduced activity
of the enzyme may also play a role in ataxia-telangi-
ectasia (Davies et al. 1989). SLC4A7 is a sodium bicar-
bonate cotransporter mainly expressed in the brain and
spinal cord (Pushkin et al. 1999). These positional can-
didate genes are currently being screened for a possible
role in the pathogenesis of HSN I with cough and GER.
Identiﬁcation of the disease gene may lead to clues to
an understanding of the cause of reﬂux at a molecular
level. Functional studies will be required to determine
whether the GER is secondary to a neuropathy affecting
the gastroesophageal sphincter or whether the reﬂux has
an unrelated etiology. The association between neurop-
athy and GER may be more common than previously
recognized, because the neuropathy may occur late in
life and may therefore be easily missed. Further studies
are continuing, to reﬁne the genetic interval and to screen
candidate genes for mutations.
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